(guidelines revised 20 January 2020 to provide more clarity on character count definition)
The regular abstract submission process for EULAR 2020 is now closed
The late edit process (change of the abstract presenting author) deadline is 15 April 2020 23:59 CET.
Regular abstract submission guidelines
- Abstract submission must be in one of the diﬀerent tracks:
A. Basic and translational research
B / C. Clinical topics by disease / area of research
D. Health Professionals in Rheumatology practice and clinical care research
E. Patient perspective / PARE research
The tracks are subdivided into 51 abstract topics. The correct category and topic must be selected to ensure correct scoring. The content of the abstract must be topic related.
- Splitting of data originating from the same study across several abstracts and/or topics is not permitted and will lead to rejection of the abstracts.
- It is mandatory to use the abstract word template provided by the system. Please read all instructions carefully before preparing your abstract. We recommend to limit your abstract to 55 lines.
- Counting towards the 3600 characters:
- Author first names, middle initials and last names
- Author affiliations
- Acknowledgements including working group
- Working group + “on behalf of” if entered
- Headings and content of the abstract word template.
- The abstract word template is structured into the following sections:
- Characters from table content including title and footnotes.
- Extra, not part of 3600 characters: Abstract title (min 15, maximum 300 characters)
- Characters not counted, but part of final abstract
- Abstract number
- Invisible characters such as spaces
- Tables (characters included count): A maximum of two tables can be included in the abstract word template with the following criteria: Combined maximum number of columns: 12 / rows: 20
Graphs / Images: A maximum of two graphs and two images each can be included. Tables turned into pictures/images are not accepted.
Abstracts can be re-edited and modiﬁed until the submission deadline (31 January 2020, 23:59 CET).
- Abstracts accepted for the congress are subject to the “EULAR embargo rules”. With the submission of an abstract, the authors agree to the embargo rules.
- Conﬂict of interest: It is the intent of EULAR to provide high quality sessions focused on educational content that is free from commercial inﬂuence or bias. Thus the submitting author of an abstract is requested to declare any potential conﬂicts of interest for all authors during the abstracts submission.
For clinical abstract submissions, the presenting author can be any of the listed authors without affiliations to industry.
For basic, translational and clinical studies below Phase 2, the presenting author can be any of the listed authors.
The inclusion of trade names/brand names is not allowed in the abstract. The mentioning of agents/molecules must follow the scientiﬁc standard for publications.
The corresponding author has the right to grant, and does grant, on behalf of all authors an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd and EULAR to publish the abstract (if accepted) in any media and to exploit all subsidiary rights.
Only abstracts that contain original data can be submitted.
Abstracts should not be submitted if the following applies:
– the abstract contains data that has been published or accepted for publication in a print or online journal.
– the abstract contains data that was presented at a scientiﬁc meeting more than 12 months prior to EULAR 2020.
Presentation of an abstract or information thereof elsewhere between 1 June 2019 and 31 January 2020 is possible. This fact must be indicated on the submission form.
Presentation of an abstract elsewhere between 1 February 2020 and 31 March 2020 is possible, if acceptance is still pending at the time of the regular abstract submission deadline (usually end of January). However, once the abstract has been accepted by EULAR it is automatically subject to the EULAR embargo rules.
Abstracts will be reviewed blinded. The reviewers will judge the abstracts according to the scientiﬁc or clinical value, relevance to EULAR, suitability of methods to aims, conclusions conﬁrmed by objective results, objectivity of statements, description of methods used, ethics, originality of work, standard of English and overall impression.
Please ensure that your abstract does not contain spelling, grammatical or scientiﬁc errors, as it will be reproduced exactly as submitted. No proofreading will be done.
Abstract acceptance will be in one of three categories: oral presentation, poster presentation, publication only.
Should the abstract be selected for oral presentation, the authors, represented by the presenting author will be required to sign an agreement to grant EULAR the right to record the presentation (audio and slide) and subsequently use it for educational purposes (with or without a fee). The full text of the agreement, the publication licence, can be found on the right side of the column.
Accepted abstracts will be published in a supplement to the Annals of Rheumatic Diseases (ARD). Information on accepted abstracts (title and authors) will also be available online about two weeks prior to the congress. Published abstracts will be available in the EULAR Abstract Archive during and after the congress.
The submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session and the time assigned by the EULAR Scientiﬁc Programme Committee. We therefore recommend submitters of abstracts to register for the congress at the time of abstract submission.
Abstracts not adhering to these guidelines will be rejected. If you do not agree with any of these rules, you should not submit an abstract. The ﬁnal decision about acceptance of an abstract will be taken by the EULAR Scientiﬁc Programme Committee. EULAR does not communicate, nor enter into correspondence on the reasons for acceptance/rejection of an abstract.
Late edit process: Presenting author may be changed through the EULAR congress system by the abstract submitter no later than 15 April 2020.
If you need to withdraw your abstract, a written statement listing the reasons for this decision must be sent to the abstract helpdesk at firstname.lastname@example.org no later than 1 April 2020.
Instructions for abstract presentations
If an abstract is selected for oral or poster presentation, the presenting author shall:
- As speciﬁed at submission, present in the the assigned session. Details will be communicated to the author by mid-April 2020.
- Sign an agreement in representation of all the abstract authors, to grant EULAR the right to record the entire presentation (audio and slide) and subsequently use it for educational purposes (with or without a fee).
- If an abstract is accepted as a poster presentation, the presenting author will be requested to be available for discussion during the corresponding poster viewing session.
- For further information contact: email@example.com